TCGA-18-3409-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- ANGIOGENESIS+0.400
- HEDGEHOG_SIGNALING+0.380
- UV_RESPONSE_DN+0.370
- TGF_BETA_SIGNALING+0.330
- HYPOXIA+0.220
- PANCREAS_BETA_CELLS+0.210
- PROTEIN_SECRETION+0.210
- COAGULATION+0.180
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- MYC_TARGETS_V2-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- E2F_TARGETS-0.350
- G2M_CHECKPOINT-0.330
- CHOLESTEROL_HOMEOSTASIS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.290
- TNFA_SIGNALING_VIA_NFKB-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.882 |
| 2 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.871 |
| 3 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.863 |
| 4 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.860 |
| 5 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.859 |
| 6 | SRR8613779 | — | D | 0.849 |
| 7 | 9ca22f6c-326b-4844-8e7d-fb076c7e1067 | — | — | 0.843 |
| 8 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.840 |
| 9 | TCGA-P3-A6T8-01A-11R-A34R-07 | — | — | 0.838 |
| 10 | SRR11296795 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |